Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.55 |
| ▸ | MMP2 | P08253 | 4/20 | 0.53 |
| ▸ | ALPI | P09923 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | XIAP | P98170 | 1/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SCN4A | P35499 | 2/20 | 0.49 |
| ▸ | ANPEP | P15144 | 1/20 | 0.48 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Solriamfetol SCHEMBL42526 | 1.00 | PKM (0.56) | PKMCYP1A2CYP2D6SMN1; SMN2NPSR1 | |
| Solriamfetol SCHEMBL30929348 | 1.00 | PKM (0.56) | PKMCYP1A2CYP2D6SMN1; SMN2NPSR1 | |
| Solriamfetol SCHEMBL30929349 | 1.00 | PKM (0.56) | PKMCYP1A2CYP2D6SMN1; SMN2NPSR1 | |
| Solriamfetol SCHEMBL42525 | 1.00 | PKM (0.56) | PKMCYP1A2CYP2D6SMN1; SMN2NPSR1 | |
| Solriamfetol SCHEMBL8430382 | 0.98 | PKM (0.54) | PKMCYP1A2CYP2D6SMN1; SMN2NPSR1 | |
| Solriamfetol SCHEMBL28413501 | 0.98 | PKM (0.54) | PKMCYP1A2CYP2D6SMN1; SMN2NPSR1 | |
| Solriamfetol SCHEMBL4987496 | 0.98 | PKM (0.54) | PKMCYP1A2CYP2D6SMN1; SMN2NPSR1 | |
| Solriamfetol SCHEMBL8426383 | 0.98 | PKM (0.54) | PKMCYP1A2CYP2D6SMN1; SMN2NPSR1 | |
| Solriamfetol SCHEMBL30518836 | 0.97 | PKM (0.53) | PKMCYP1A2CYP2D6SMN1; SMN2NPSR1 | |
| Solriamfetol SCHEMBL30518840 | 0.95 | PKM (0.51) | PKMCYP1A2CYP2D6SMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 725 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688731-A1 | PROCESS FOR PREPARING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | INKE, S.A. (ES) | 2026-02-11 | — | — | EP | claimed |
| US-20250367299-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ZEVRA THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | claimed |
| US-20250352476-A1 | FORMULATIONS OF (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | AXSOME MALTA LTD (MT) | 2025-11-20 | — | — | US | claimed |
| US-20250339399-A1 | SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM | BEIJING CREATRON INSTITUTE OF PHARMACEUTICAL RES CO LTD (CN) | 2025-11-06 | — | — | US | claimed |
| EP-4633638-A1 | TREATMENT OF PSYCHOLOGICAL FACTORS AFFECTING OTHER MEDICAL CONDITIONS (PFAOMC) | Luminous Mind Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| US-12390419-B2 | Formulations of (R)-2-amino-3-phenylpropyl carbamate | AXSOME MALTA LTD. (MT) | 2025-08-19 | — | — | US | claimed |
| US-20250186591-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ZEVRA THERAPEUTICS INC (US) | 2025-06-12 | — | — | US | claimed |
| US-20250114322-A1 | METHODS AND COMPOSITIONS FOR TREATING EXCESSIVE SLEEPINESS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-04-10 | — | — | US | claimed |
| US-12263145-B2 | Methods of administering solriamfetol to lactating women | AXSOME MALTA LTD. (MT) | 2025-04-01 | — | — | US | claimed |
| CN-102695502-B | Compositions for treating drug addiction and improving drug addiction-related behavior | SK BIOPHARMACEUTICALS CO LTD | 2014-12-24 | — | — | CN | claimed |
| CN-102781436-B | Methods for treating fibromyalgia syndrome | SK BIOPHARMACEUTICALS CO LTD | 2014-01-08 | — | — | CN | claimed |
| CN-102762201-B | Methods for treating attention-deficit/hyperactivity disorder | SK BIOPHARMACEUTICALS CO LTD | 2013-12-18 | — | — | CN | claimed |
| CN-103025326-A | Methods of treating restless legs syndrome | SK BIOPHARMACEUTICALS CO LTD | 2013-04-03 | — | — | CN | claimed |
| CN-102985085-A | Methods for treating bipolar disorder | SK BIOPHARMACEUTICALS CO LTD | 2013-03-20 | — | — | CN | claimed |
| CN-102781436-A | Methods for treating fibromyalgia syndrome | SK HOLDINGS CO LTD | 2012-11-14 | — | — | CN | claimed |
| CN-102762201-A | METHODS FOR TREATING ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | SK HOLDINGS CO LTD | 2012-10-31 | — | — | CN | claimed |
| CN-101217949-B | Treating Sleep-Wake Disorders | SK CORP | 2012-10-17 | — | — | CN | claimed |
| CN-102695502-A | Compositions for treating drug addiction and improving drug addiction-related behavior | SK HOLDINGS CO LTD | 2012-09-26 | — | — | CN | claimed |
| CN-101217949-A | Treating Sleep-Wake Disorders | SK CORP (KR) | 2008-07-09 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12390419-B2 | Formulations of (R)-2-amino-3-phenylpropyl carbamate | PRCP, GRPR, CPS1 | PKM 2187/4885CYP1A2 1001/4885CYP2D6 946/4885 |
| US-20250114322-A1 | METHODS AND COMPOSITIONS FOR TREATING EXCESSIVE SLEEPINESS | CHAT, PNMT, HCRTR1 | PKM 1169/4885CYP1A2 1015/4885CYP2D6 2042/4885 |
| US-20250186591-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | HSD17B10, HSD17B12, HSD17B14 | PKM 1909/4885CYP1A2 741/4885CYP2D6 664/4885 |
| US-20250352476-A1 | FORMULATIONS OF (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | CPS1, PRCP, GLS2 | PKM 1586/4885CYP1A2 527/4885CYP2D6 392/4885 |
| US-20250339399-A1 | SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM | S100A8, TP53, AQP1 | PKM 3085/4885CYP1A2 4394/4885CYP2D6 4115/4885 |
| US-12263145-B2 | Methods of administering solriamfetol to lactating women | PGF, OGFRL1, OGFR | PKM 1232/4885CYP1A2 1089/4885CYP2D6 199/4885 |
| US-20250367299-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | HSD17B10, HSD17B12, HSD17B14 | PKM 1909/4885CYP1A2 741/4885CYP2D6 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.